The group has blamed placebo “overperformance” on a high proportion of less-sick patients.
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Biogen looks beyond aducanumab, and late-stage data loom for Lilly, Bristol Myers Squibb and Novartis.